Abstract
Over the past years intense efforts have been made to identify tumor specific or tumor associated markers which could be immunogenic in humans and animals. A considerable amount of data, which at least proves the existence of tumor associated antigens in humans, has been collected. Immunological techniques applied to diagnosis in oncology have allowed improvement, both in terms of sensitivity and specificity, in the area of pathology as well as in the laboratory and in nuclear medicine. More recently, the use of monoclonal antibodies (MAbs) derived by somatic hybridization [1] has allowed further improvement of results obtained with conventional antisera and opened new pathways in the field of research. In fact, these reagents possess a peculiar characteristic, that is, monospecificity, which makes them particularly suitable for immunological applications where the target of the immune response, the putative tumor antigen, is often undefined, possibly poorly immunogenic and difficult to identify.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kühler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 246, 495–7.
Colcher, D., Milenic, D., Roselli, M. et al. (1989) Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res., 49, 1738–45.
Liu, A.Y., Robinson, R.R., Hellström, K.E. et al. (1987) Chimeric mouse-human IgCl antibody that can mediate lysis of cancer cells. Proc. Natl Acad. Sci. USA, 84, 3439–43.
Miotti, S., Canevari, S., Ménard, S. et al. (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.Int. J. Cancer, 39, 297–303.
Wilson, B.S., Imai, K., Natali, P.C. and Ferrone, S. (1981) Distribution and molecular characterization of a cell surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int. J. Cancer, 28, 293–300.
Dillman, R.O. (1990) Human antimouse and antiglobulin responses to monoclonal antibodies. Immunoconj. Radiopharm., 3,1–15.
Adair, J.R. (1992) Engineering antibodies for therapy. Immunol. Rev., 130, 5–400.
Orlandi, R., Gussow, D.H., Jones, P.T. and Winter, G. (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 86, 3833–7.
Rosenberg, S.A. (1992) The immunotherapy and gene therapy of cancer.J. Clin. Pathol, 10, 180–99.
Roosnek, E. and Lanzavecchia, A. (1989) Triggering T cells by otherwise inert hybrid anti-CD3/anti-tumor antibodies requires encounter with the specific target cell. J. Exp. Med., 170,297–302.
Lanzavecchia, A. and Scheidegger, D. (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol, 17,105–11.
Perez, P., Hoffman, R.W., Titus, J.A. and Segal, D.S. (1986) Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 cross linked to anti-target antibodies. J. Exp. Med., 163,166–78.
Staerz, U. and Bevan, M.J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl Acad. ScL USA, 83,1453–7.
Mezzanzanica, D., Canevari, S., Ménard, S. et al. (1988) Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer, 41, 609–15.
Glennie, MJ., McBride, H.M., Worth, A.T. and Stevenson, G.T. (1987) Preparation and performance of bispecific F(ab02 antibody containing thioether-linked Fab’ fragments. J.Immunol, 139, 2367–75.
Jung, G., Honsik, C.J., Reisfeld, R.A. and Muller-Eberhard, H.J. (1986) Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc. Natl. Acad. Sci. USA, 83, 4479–83.
Pupa, S.M., Canevari, S., Fontanelli, R. et al. (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int. J. Cancer, 42, 455–9.
Coney, L.R., Tomassetti, A., Carayannopoulos, L. et al. (1991) Cloning of a tumor-associated antigen: MOvl8 and MOvl9 antibodies recognize a folate-binding protein. Cancer Res., 51, 6125–32.
Buraggi, G.L., Crippa, F., Landoni, L. et al. (1988) A new monoclonal antibody (MOvl8) against ovarian cancer for imaging and therapy. In Radioactive Isotopes in Clinical Medicine and Research, (eds. R. Hoffer and H. Bergman), Schattauer, Stuttgart, pp. 57–62.
Crippa, F., Buraggi, G.L., Di Re, E.et al. (1991) Radioimmunoscintigraphy of ovarian cancer with the MOvl8 monoclonal antibody.Eur. J. Cancer, 27, 724–9.
Segal, D.M., Qian, J., Titus, J.A. et al. (1992) Targeted cytokine production. Int. J. Cancer, 52 (Suppl), 36–8.
Mezzanzanica, D., Neblock, D.S., Garrido, M.A. et al. (1990) In vivo retargeting of human T cells against human ovarian carcinoma by bifunctional F(ab’)2 antibodies. Antib. Immun. Radiopharm., 3, 81
Nitta, T., Sato, K., Yagita, H. et al. (1990) Preliminary trial of specific targeting therapy against malignant glioma.Lancet, 335, 368–71.
Bolhuis, R.L.H., Lamers, C.H.J., Goey, H.S. et al. (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int. J. Cancer, 7, 78–81.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Chapman & Hall
About this chapter
Cite this chapter
Colnaghi, M.I. (1995). Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells. In: Sharp, F., Mason, P., Blackett, T., Berek, J. (eds) Ovarian Cancer 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-0136-4_32
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0136-4_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-0138-8
Online ISBN: 978-1-4757-0136-4
eBook Packages: Springer Book Archive